Liquidia (LQDA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
19 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, welcoming all virtual participants and outlining the virtual-only format, enabling remote voting and Q&A participation.
The agenda and Rules of Conduct were posted online, detailing procedures for voting and submitting questions.
Technical and legal formalities were addressed to ensure the meeting was duly authorized.
Board and executive committee updates
Directors and executive officers were introduced, including those present and absent.
The independent registered public accounting firm, PricewaterhouseCoopers, was introduced.
Shareholder proposals
Three proposals were presented: election of Class 2 directors, ratification of the accounting firm, and advisory approval of executive compensation.
Latest events from Liquidia
- YUTREPIA's rapid growth and pipeline expansion drive strong revenue and market leadership.LQDA
Jefferies Global Healthcare Conference 20263 Jun 2026 - YUTREPIA's strong launch and expanding pipeline drive growth and innovation in PAH and PH-ILD.LQDA
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - YUTREPIA's rapid growth and innovation position it to capture a $1B+ market by 2027.LQDA
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 delivered strong YUTREPIA sales, profitability, and cash growth amid litigation risks.LQDA
Q1 202611 May 2026 - Virtual annual meeting set for June 16, 2026, with board-backed votes on directors, auditor, and pay.LQDA
Proxy filing24 Apr 2026 - Record-breaking YUTREPIA launch fuels growth, with key votes on directors, auditor, and pay.LQDA
Proxy filing24 Apr 2026 - Strong commercial uptake, expanding clinical programs, and profitability support a $1B revenue goal by 2027.LQDA
25th Annual Needham Virtual Healthcare Conference15 Apr 2026 - Rapid launch and profitability drive $148.3M sales and 17% Q4 market share in 2025.LQDA
Q4 20255 Mar 2026 - Yutrepia and L606 advance inhaled treprostinil with strong data, FDA approval, and global expansion.LQDA
R&D Day 20253 Feb 2026